Theramex HQ UK Limited acquires Viatris Inc (2023)

Deal facts

Buyer: Theramex HQ UK Limited
Target: Viatris Inc
Deal value: Not disclosed
Announced: 20 November 2023
Status: Cleared
Sector: Healthcare
Country: United States
Consideration: cash

Sources

UK_CMA_GOVUK

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

21 Nov 2023CMA Phase 1 clearance
Theramex/European Rights to Viatris’ Femoston and Duphaston products
The CMA investigated the anticipated acquisition by Theramex HQ UK Limited of the European Rights to Viatris’ Femoston and Duphaston Products. Statutory timetable Phase 1 Action 12 August 2024 Undertakings in lieu of reference accepted 24 June 2024 Consultation on proposed undertakings in lieu of reference 4 April 2024 Deadline for phase 1 decision 6 Februa
UK CMA

OpinionExit Mode editorial

We see a clear signal in the Theramex HQ UK Limited acquisition of Viatris Inc, announced on 20 November 2023. A UK-based buyer moving to acquire a US target in the healthcare sector for cash is a notable shift in the cross-border M&A landscape. This strategic acquisition demonstrates that British life sciences firms are willing and able to deploy capital abroad, even when the target is a substantial entity based across the Atlantic. The deal has already received clearance, which removes a significant layer of uncertainty that often plagues international transactions.

The all-cash consideration structure is particularly instructive for the SME founder reading this. Cash deals eliminate the dilution risk associated with share swaps and provide immediate liquidity, a feature that often appeals to founders seeking a clean exit. However, this structure also places the entire valuation burden on the buyer's balance sheet. For a UK acquirer, this implies strong internal capital reserves or access to debt financing that can withstand the scrutiny of lenders and regulators. The fact that the transaction is cleared suggests that competition authorities in both the UK and the US have found no anti-competitive concerns, a vital milestone for any cross-border deal in the regulated healthcare space.

Regulatory clearance is rarely a given when a UK entity targets a US company, given the heightened scrutiny from the CMA and the potential for overlapping FCA or SEC requirements. The successful clearance here indicates a robust regulatory strategy was executed from the outset. It also highlights that the sector remains attractive despite global economic headwinds. The absence of an earn-out or deferred payment mechanism in the public record suggests the buyer has full confidence in the target's standalone value, a rare and powerful vote of confidence in the current market.

For the SME founder preparing for a sale, the lesson is to prioritise regulatory readiness before engaging with potential buyers. Ensure your compliance framework can withstand a rigorous CMA or international competition review, as this is often the make-or-break factor in cross-border transactions.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2023 deals More strategic acquisition deals More from Theramex HQ UK Limited All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history